pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations is a pharma organization headquartered in Herstal, BE. It trades on NYSE under ticker TLX. Primary therapeutic focus areas include Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carc
Rue de Hermée 255, Herstal, Région wallonne 4040, BE HQ
2015 Founded
14 Employees
Public company Type
TLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
177Lu girentuximab
Phase 2 · small molecule · Advanced Cancer
177Lu girentuximab for Advanced Cancer is a Phase 2 program (small_molecule) at Telix Innovations with 1 ClinicalTrials.gov record(s).
Internal code 2021-0911
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Telix Innovations
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Cancer
- Status
- active
- Trials
- 1